Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin

Eur J Heart Fail. 2002 Oct;4(5):583-6. doi: 10.1016/s1388-9842(02)00091-0.


Aims: The purpose of this study was to determine that the administration of an angiotensin converting enzyme (ACE) inhibitor enalapril would confer protection against doxorubicin-induced experimental heart failure, and attenuate the development of left ventricular dysfunction.

Methods: Seventeen dogs were chronically instrumented with an intracoronary catheter and received doxorubicin weekly for 4 weeks. Animals were assigned to two groups: group 1: untreated heart failure; and group 2: simultaneous enalapril administration (5 mg twice a week). Hemodynamic data were obtained at week 0 and 12. Echocardiography was performed weekly.

Results: Survival improved with simultaneous enalapril administration (36% in group 1 vs. 100% in group 2, P=0.04). The increase in the left ventricular end-diastolic pressure was significantly reduced at week 12 (17+/-1 mmHg in group 1 vs. 9+/-1 mmHg in group 2, P=0.0042). The fall in left ventricular stroke work index was significantly prevented (52% in group 1 vs. 21% in group 2, P=0.006). The increase in right ventricular end-diastolic diameter was significantly reduced by enalapril prophylaxis.

Conclusion: Simultaneous treatment with enalapril was beneficial in the prevention of doxorubicin-induced cardiomyopathy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Animals
  • Antineoplastic Agents*
  • Blood Pressure / drug effects
  • Disease Models, Animal
  • Dogs
  • Doxorubicin*
  • Enalapril / therapeutic use
  • Heart Failure / chemically induced
  • Heart Failure / drug therapy
  • Heart Rate / drug effects
  • Male
  • Models, Cardiovascular
  • Stroke Volume / drug effects
  • Time Factors
  • Treatment Outcome
  • Vascular Resistance / drug effects
  • Ventricular Dysfunction, Left / chemically induced*
  • Ventricular Dysfunction, Left / drug therapy*


  • Angiotensin-Converting Enzyme Inhibitors
  • Antineoplastic Agents
  • Enalapril
  • Doxorubicin